Duloxetine: Pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 5, 2005, Pages 707-713

  McIntyre, Roger S ^a,b,c   Konarski, Jakub Z ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Duloxetine; Major depressive disorder; Noradrenaline; Pain; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANALGESIA; BACKACHE; CHRONIC DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG POTENCY; DRUG RECEPTOR BINDING; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; MAJOR DEPRESSION; PHYSICAL DISEASE; PROBABILITY; REMISSION; REVIEW; SHOULDER PAIN; SYMPTOMATOLOGY;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; ECONOMICS, PHARMACEUTICAL; HUMANS; PAIN; PAIN MEASUREMENT; THIOPHENES;

EID: 19044377101     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.5.707     Document Type: Review

References (65)

1. DEMYTTENAERE K, BRUFFAERTS R, POSADA-VILLA J et al.: Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA (2004) 291:2581-2590.
2. LEPINE JP, GASTPAR M, MENDLEWICZ J, TYLEE A: Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. (1997] 12:19-29.
3. WARAICH P, GOLDNER EM, SOMERS JM, HSU L: Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can. J. Psychiatry (2004) 49:124-138.
4. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders: American Psychiatric Press. Inc., Washington DC (1994).
5. KATON W, SCHULBERG H: Epidemiology of depression in primary care. Gen. Hosp. Psychiatry (19921 14:237-247.
6. KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8-19.
7. KENDLER KS: Hierarchy and heritability: the role of diagnosis and modeling in psychiatric genetics. Am. J. Psychiatry (2002) 159:515-518.
8. KENDLER KS, GARDNER CO, PRESCOTT CA: Toward a comprehensive developmental model for major depression in women. Am. J. Psychiatry (2002) 159:1133-1145.
9. BERTO P, D'ILARIO D, RUFFO P, DI VR, RIZZO F: Depression: cost-of-illness studies in the international literature, a review. J. Ment. Health Policy Econ. (2000) 3:3-10.
10. MCINTYRE RS, O'DONOVAN C: The human cost of not achieving full remission in depression. Can. J. Psychiatry (2004) 49:10S-16S.
11. GREENBERG PE, STIGLIN LE, FINKELSTEIN SN, BERNDT ER: The economic burden of depression in 1990. J. Clin. Psychiatry (1993) 54:405-418.
12. MURRAY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 349:1436-1442.
13. KESSLER RC, BERGLUND P, DEMLER O et al.: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 289:3095-3105.
14. GOLDENBERG DL, BURCKHARDT C, CROFFORD L: Management of fibromyalgia syndrome. JAMA (2004) 292:2388-2395.
15. MENDELL JR, SAHENK Z: Clinical practice. Painful sensory neuropathy. N. Engl. J. Med. (2003) 348:1243-1255.
16. KRISHNAN ST, RAYMAN G: New treatments for diabetic neuropathy: symptomatic treatments. Curr. Diab. Rep. (2003) 3:459-467.
17. STAHL SM, ZHANG L, DAMATARCA C, GRADY M: Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J. Clin. Psychiatry (2003) 64(Suppl. 14):6-17.
18. OHAYON MM, SCHATZBERG AF: Using chronic pain to predict depressive morbidity in the general population. Arch. Gen. Psychiatry (2003) 60:39-47.
19. JACKSON JL, HOUSTON JS, HANLING SR, TERHAAR KA, YUN JS: Clinical predictors of mental disorders among medical outpatients. Arch. Intern. Med. (2001) 161:875-879.
20. KATON W, SULLIVAN M, WALKER E: Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann. Intern. Mead. (2001) 134:917-925.
21. KROENKE K, SPITZER RL, WILLIAMS JB et al.: Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch. Fam. Med. (1994) 3:774-779.
22. SIMON GE, VONKORFF M: Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Am. J. Psychiatry ( 1991) 148:1494-1500,
23. GERBER PD, BARRETT J, BARRETT J, MANHEIMER E, WHITING R, SMITH R: Recognition of depression by internists in primary care: a comparison of internist and 'gold standard' psychiatric assessments. J Gen Intern. Med. (1989) 4:7-13.
24. KATON W: Depression: relationship to somatization and chronic medical illness. J. Clin. Psychiatry (1984) 45:4-12.
25. GERBER PD, BARRETT JE, BARRETT JA et al.: The relationship of presenting physical complaints to depressive symptoms in primary care patients. J. Gen. Intern. Med. (1992) 7:170-173.
26. PAPAKOSTAS GI, PETERSEN T, HUGHES ME, NIERENBERG AA, ALPERT JE, FAVA M: Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res. (2004) 126:287-290.
27. BASBAUM AI, FIELDS HL: Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Ann. Rev. Neurosci. ( 1984) 7:309-338.
28. JONES SL: Descending noradrenergic influences on pain. Prog. Brain Res. (1991) 88:381-394.
29. RICHARDSON BP: Serotonin and nociception. Ann. NY Acad. Sci. (1990) 600:511-519.
30. KELLER MB: Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA (2003) 289:3152-3160.
31. GEDDES JR, CARNEY SM, DAVIES C et al.: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet (2003) 361:653-661.
32. JUDD LL, AKISKAL HS, MASER JD et al.: Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J. Affect. Disord. (1998) 50:97-108.
33. JUDD LL, AKISKAL HS, MASER JD et al.: A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch. Gen. Psychiatry (1998) 55:694-700.
34. JUDD LL, PAULUS MJ, SCHETTLER PJ et al.: Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am. J. Psychiatry (2000) 157:1501-1504.
35. KELLER MB: Remission versus response: the new gold standard of antidepressant care. J. Clin. Psychiatry (2004) 65(Suppl. 4):53-59.
36. THASE ME, ENTSUAH AR, RUDOLPH RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry (2001) 178:234-241.
37. KENNEDY SH, LAM RW, COHEN NL, RAVINDRAN AV: Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J. Psychiatry (2001) 46(Suppl. 1):38S-58S.
38. SMITH D, DEMPSTER C, GLANVILLE J, FREEMANTLE N, ANDERSON I: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry (2002) 180:396-404.
39. FREEMANTLE N, ANDERSON IM, YOUNG P: Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Metaregression analysis. Br. J. Psychiatry (2000) 177:292-302.
40. SHELTON RC: The dual-action hypothesis: does pharmacology matter? J. Clin. Psychiatry (2004) 65(Suppl. 17):5-10.
41. THASE ME: Introduction: the dual-action debate: does pharmacology matter? J. Clin. Psychiatry (2004) 65(Suppl. 17):3-4.
42. DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl) (1986) 90:131-138.
43. DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J. Affect. Disord. (1990) 18:289-299.
44. ENTSUAH AR, HUANG H, THASE ME: Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry (2001) 62:869-877.
45. WONG DT, BYMASTER FP, MAYLE DA, REID LR, KRUSHINSKI JH, ROBERTSON DW: LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology (1993) 8:23-33.
46. LANTZ RJ, GILLESPIE TA, RASH TJ et al.: Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos. (2003) 31:1142-1150.
47. SKINNER MH, KUAN HY, PAN A et al.: Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther. (2003) 73:170-177.
48. VAN KERREBROECK P, ABRAMS P, LANGE R et al.: Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG (2004) 111:249-257.
49. GOLDSTEIN DJ, MALLINCKRODT C, LU Y, DEMITRACK MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry (2002) 63:225-231.
50. DETKE MJ, WILTSE CG, MALLINCKRODT CH, MCNAMARA RK, DEMITRACK MA, BITTER I: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. (2004) 14:457-470.
51. DETKE MJ, LU Y, GOLDSTEIN DJ, HAYES JR, DEMITRACK MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry (2002) 63:308-315.
52. GOLDSTEIN DJ, LU Y, DETKE MJ, HUDSON J, IYENGAR S, DEMITRACK MA: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics (2004) 45:17-28.
53. FAVA M, MALLINCKRODT CH, DETKE MJ, WATKIN JG, WOHLREICH MM: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry (2004) 65:521-530.
54. FRITZSCHE K, SANDHOLZER H, BRUCKS U et al.: Psychosocial care by general practitioners - where are the problems? Results of a demonstration project on quality management in psychosocial primary care. Int. J. Psychiatry Med. (1999) 29:395-409.
55. KATON WJ: Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol. Psychiatry (2003) 54:216-226.
56. THOMPSON D: Toward a pharmacoeconomic model of neuropathic pain. Clin. J. Pain (2002) 18:366-372.
57. SOLBERG LI, HURLEY JS, ROBERTS MH et al.: Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. Am. J. Manag. Care (2004) 10:753-759.
58. MCINTYRE RS, KONARSKI JZ, YATHAM LN: Comorbidity in bipolar disorder: a framework for rational treatment selection. Human Psychopharmacology (2004) 19:369-386.
59. ROWBOTHAM MC, GOLI V, KUNZ NR, LEI D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain (2004) 110:697-706.
60. FORSSELL H, TASMUTH T, TENOVUO O, HAMPF G, KALSO E: Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J. Orosac. Pain (2004) 18:131-137.
61. REUBEN SS, MAKARI-JUDSON G, LURIE SD: Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J. Pain Symptom Manage. (2004) 27:133-139.
62. SINDRUP SH, BACH FW, MADSEN C, GRAM LF, JENSEN TS: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology (2003) 60:1284-1289.
63. BENDTSEN L, JENSEN R: Mirtazapme is effective in the prophylactic treatment of chronic tension-type headache. Neurology (2004) 62:1706-1711.
64. BYMASTER FP, DRESHFIELD-AHMAD LJ et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology (2001) 25:871-880.
65. TATSUMI M, GROSHAN K, BLAKELY RD, RICHELSON E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. (1997) 340:249-258.